Abstract
Being the second most-frequent type of age-related neurodegenerative dementia, dementia with Lewy bodies (DLB) is currently exerting a huge burden on the healthcare system. Since DLB lacks a definitive biomarker profile, a diagnostic tool becomes indispensable for effectively distinguishing DLB from other neurodegenerative diseases with overlapping neuropathological and clinical features in their early stages. In this context, saliva could serve as a viable alternative to more invasive and costly methods, providing clear advantages in terms of safety and affordability. This is a commentary serving to contextualize the findings of D’Antonio et al., featured in the Journal of Alzheimer's Disease.
Keywords
Get full access to this article
View all access options for this article.
